Xiaoqin Liu, Nhung Th Trinh, Naomi R Wray, Angela Lupattelli, Clara Albiñana, Esben Agerbo, Bjarni J Vilhjálmsson, Veerle Bergink, Trine Munk-Olsen
Pregnant women on antidepressants must balance potential fetal harm with the relapse risk. While various clinical and sociodemographic factors are known to influence treatment decisions, the impact of genetic factors remains unexplored. We conducted a cohort study among 2,316 women with diagnosed affective disorders who had redeemed antidepressant prescriptions six months before pregnancy, identified from the Danish Integrated Psychiatric Research study. We calculated polygenic risk scores (PGSs) for major depression (MDD), bipolar disorder (BD), and schizophrenia (SCZ) using individual-level genetic data and summary statistics from genome-wide association studies...
February 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology